DayTwo is an Israeli medtech startup which uses artificial intelligence to sequence the gut microbiome to create precision nutrition-based food prescriptions to balance blood sugar levels after meals. Its solutions are designed to improve the health of people with diabetes and other metabolic diseases. The company has raised $37 million from investors like aMoon of Marius Nacht and Dr. Yair Schindel, 10D of Yahal Zilka, and Cathay Innovation Ventures.
This round raises the capital invested in DayTwo to date to $85 million.
DayTwo was founded by Marius Nacht (one of the founders of Check Point and an investor in start-ups) together with Lihi Segal (CEO) and Yuval Ofek. The company calls itself a leader in precision medicine with the world’s “largest and highest resolution microbiome discovery platform.” It offers a sustainable path to remission for metabolic disease (diabetes, prediabetes, clinical obesity, non-alcoholic fatty liver disease).
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
In recent years Israel has become known as the startup state or Startup Nation. The country has had multi-billion dollar exits for numerous software and security companies. But Startup Nations is also known for its medtech startups. Israel has always been a center for medical research and innovation. Now put that together with its startup culture and you have medtech nation.
DayTwo boasts that its solution for metabolic disease improves health outcomes and reduces or eliminates prescription medications by improving Time in Range and lowering A1C, through gut microbiome profiling, artificial intelligence and dedicated virtual care.
Metabolic disease is the first condition to be addressed by DayTwo’s microbiome discovery platform, and along with artificial intelligence and dedicated virtual care, offers an engaging and effective care plan for chronic disease.
The funds raised will be used for the company’s first product, which it says is already helping over 70,000 users in Israel and the U.S. It is based on pioneering research and technology that was developed at the Weizmann Institute by Professors Eran Segal and Eran Elinav. The solution uses artificial intelligence (AI), the sequencing of the gut microbiome and other clinical measures to create precision nutrition-based food prescriptions to balance blood sugar levels after meals.
DayTwo is proud to announce the launch of EATS™—a new Behavior Change Model for addressing depression in people with diabetes. We’re reinventing the metabolic disease care model by incorporating a unique approach that addresses mental health. https://t.co/8lJgkzK9WL #depression pic.twitter.com/9wybDZSa2m
— DayTwo (@daytwohealth) May 28, 2021
“Last year we significantly expanded the company’s development center,” said Adi Lev, DayTwo’s Deputy CEO for Research & Development. “We invested in Devops infrastructure and advanced cloud architecture which enable our developers to build solutions to the highest standards, very quickly and with the most up-to-date technologies available.
The current round of funding comes after the company demonstrated significant clinical impact on participants in the DayTwo program in the U.S. including decreased blood sugar levels and a significant decrease in prescription medication costs. As a result, DayTwo is working with large employers and health plans in the U.S. market. In the Israeli market, the company is collaborating with Clalit Health Services, which provides DayTwo’s solution to its members, and the company expects to launch a similar collaboration with Maccabi Health Services.
According to Lihi Segal, CEO and founder of DayTwo, “Over the past year we have devoted most of our efforts and focus to the U.S. market. It is very important to show the clinical impact and improved health of users, as well as savings in healthcare costs. Our solution leads to a significant and rapid reduction in healthcare costs due to a reduction in prescription medication, fewer visits to the doctor, fewer complex surgical procedures with accompanying complications in the case of diabetes and metabolic diseases. We will continue to invest resources, expand our development center in Israel, and bring in expert developers in order to intensify our research on intestinal bacteria and develop additional solutions with real clinical impact.”